4.7 Article

Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 76, 期 9, 页码 1018-1030

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2020.07.005

关键词

aortic stenosis; bicuspid aortic valve; transcatheter aortic valve implantation

资金

  1. Abbott Vascular
  2. Edwards Lifesciences
  3. Medtronic
  4. Bracco
  5. Boston Scientific
  6. Biotronik
  7. Abbott
  8. Amgen
  9. Bristol-Myers Squibb
  10. Bayer
  11. Cardinal Health
  12. CardioValve
  13. CSL Behring
  14. Daiichi-Sankyo
  15. Johnson Johnson
  16. Querbet
  17. Polares
  18. Sanofi
  19. Terumo
  20. Sinomed
  21. Abiomed
  22. MedAlliance
  23. V-Wave
  24. Xeltis

向作者/读者索取更多资源

BACKGROUND Bicuspid aortic stenosis accounts for almost 50% of patients undergoing surgical aortic valve replacement in the younger patients. Expanding the indication of transcatheter aortic valve replacement (TAVR) toward lower-risk and younger populations will lead to increased use of TAVR for patients with bicuspid aortic valve (BAV) stenosis despite the exclusion of bicuspid anatomy in all pivotal clinical trials. OBJECTIVES This study sought to evaluate the association of BAV morphology and outcomes of TAVR with the new-generation devices. METHODS Patients with BAV confirmed by central core laboratory computed tomography (CT) analysis were included from the international multicenter BAV TAVR registry. BAV morphology including the number of raphe, calcification grade in raphe, and leaflet calcium volume were assessed with CT analysis in a masked fashion. Primary outcomes were all-cause mortality at 1 and 2 years, and secondary outcomes included 30-day major endpoints and procedural complications. RESULTS A total of 1,034 CT-confirmed BAV patients with a mean age of 74.7 years and Society of Thoracic Surgeons score of 3.7% underwent TAVR with contemporary devices (n = 740 with Sapien 3; n = 188 with Evolut R/Pro; n = 106 with others). All-cause 30-day, 1-year, and 2-year mortality was 2.0%, 6.7%, and 12.5%, respectively. Multivariable analysis identified calcified raphe and excess leaflet calcification (defined as more than median calcium volume) as independent predictors of 2-year all-cause mortality. Both calcified raphe plus excess leaflet calcification were found in 269 patients (26.0%), and they had significantly higher 2-year all-cause mortality than those with 1 or none of these morphological features (25.7% vs. 9.5% vs. 5.9%; log-rank p < 0.001). Patients with both morpho-logical features had higher rates of aortic root injury (p < 0.001), moderate-to-severe paravalvular regurgitation (p = 0.002), and 30-day mortality (p = 0.016). CONCLUSIONS Outcomes of TAVR in bicuspid aortic stenosis depend on valve morphology. Calcified raphe and excess leaflet calcification were associated with increased risk of procedural complications and midterm mortality. (c) 2020 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据